News
Media
Multimedia Series
Conferences
Partners
CME/CE
Resources
Advisory Board
Subscribe

Spotlight -

This Year In Medicine 2025

Payal Kohli, MD, FACC

Articles by Payal Kohli, MD, FACC

Disparities in Managing Patients

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 28th 2023

Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.

LDL Cholesterol as a Performance Measure

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 21st 2023

The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.

Reasons for Not Reaching Thresholds

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 21st 2023

The reasons many patients do not reach LDL-cholesterol thresholds.

Real-World Outcomes Data on Failure to Achieve LDL-C Thresholds

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 14th 2023

Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.

Real-World Data on Achieving LDL Thresholds

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 14th 2023

Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.

New Guidance in Lowering LDL-C

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 7th 2023

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.

LDL-C and Cardiovascular Disease Risk

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 7th 2023

Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.

Trending on HCPLive

OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity

A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease

Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib

CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports

Red Flags for Misdiagnosed Type 2, When to Order Antibodies and C‑Peptide